148 related articles for article (PubMed ID: 33691573)
1. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Arora S; Vachhani P; Bachiashvili K; Jamy O
Leuk Lymphoma; 2021 Sep; 62(9):2292-2294. PubMed ID: 33691573
[No Abstract] [Full Text] [Related]
2. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
Kong J; Chen N; Li M; Zhang J; Wu X; Zong L; Wu D; Song B; Qiu H
Ann Hematol; 2022 Mar; 101(3):697-699. PubMed ID: 33954816
[No Abstract] [Full Text] [Related]
3. [Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].
Kong JY; Zong LH; Pu Y; Liu Y; Kong X; Li MY; Zhang J; Song BQ; Xue SL; Tang XW; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):649-653. PubMed ID: 37803838
[No Abstract] [Full Text] [Related]
4. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
Zhu Y; Dai Y; Tang X
Ann Hematol; 2022 Nov; 101(11):2525-2528. PubMed ID: 36063200
[No Abstract] [Full Text] [Related]
5. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Wan CL; Zou JY; Qiao M; Yin J; Shen XD; Qiu QC; Liu SB; Xue SL
Leuk Lymphoma; 2021 Dec; 62(13):3300-3303. PubMed ID: 34323656
[No Abstract] [Full Text] [Related]
6. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Zhang X; Li J; Jin J; Yu W
Ann Hematol; 2020 Feb; 99(2):395-397. PubMed ID: 31879788
[No Abstract] [Full Text] [Related]
7. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Aumann S; Shaulov A; Haran A; Gross Even-Zohar N; Vainstein V; Nachmias B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142863
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia.
Wang H; Yang C; Shi T; Zhang Y; Qian J; Wang Y; Hu Y; Mao L; Ye X; Liu F; Xi Z; Shou L; Fu C; Naranmandura H; Jin J; Zhu HH
Blood Cancer J; 2022 Jan; 12(1):20. PubMed ID: 35091541
[No Abstract] [Full Text] [Related]
12. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
Farhadfar N; Li Y; May WS; Adams CB
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):246-251. PubMed ID: 32199933
[TBL] [Abstract][Full Text] [Related]
14. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
[TBL] [Abstract][Full Text] [Related]
15. Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients.
Wei S; Gu R; Song Y; Yan Z; Hu Y; Lin D; Liu K; Zhou C; Zhang G; Wang Y; Wang J; Mi Y
Br J Haematol; 2022 Dec; 199(5):772-776. PubMed ID: 36161433
[No Abstract] [Full Text] [Related]
16. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
17. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Short NJ; Konopleva M; Kadia T; Kebriaei P; Daver N; Huang X; Masarova L; Cook R; Jain N; Jabbour E; Kantarjian H; Ravandi F
Am J Hematol; 2021 Jul; 96(7):E229-E232. PubMed ID: 33780038
[No Abstract] [Full Text] [Related]
18. Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
Diamanti P; Ede BC; Dace PE; Barendt WJ; Cox CV; Hancock JP; Moppett JP; Blair A
Br J Haematol; 2021 Feb; 192(3):577-588. PubMed ID: 32452017
[TBL] [Abstract][Full Text] [Related]
19. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
20. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
Tang H; Jia W; Jia S; Dong R; Gao S; Feng J; Dong H; Gu H; Zhang T; Yuan R; Liu X; Cheng L; Zhou S; Gao G
Am J Hematol; 2024 Jun; 99(6):1177-1179. PubMed ID: 38482543
[No Abstract] [Full Text] [Related]
[Next] [New Search]